KAMEALYA FARRELL: Open Payments
NPI 1215462999 · SULLIVAN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,377 in 78 payments from 19 companies in 2025. Trend: 2023 $843 · 2024 $1,032 · 2025 $1,377
Food & beverage: $1,377
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $358 |
| Novo Nordisk Inc | 12 | $170 |
| AstraZeneca Pharmaceuticals LP | 5 | $147 |
| SANOFI-AVENTIS U.S. LLC | 3 | $93 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $85 |
| Lilly USA, LLC | 3 | $68 |
| Gilead Sciences, Inc. | 3 | $62 |
| Exact Sciences Corporation | 3 | $58 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $57 |
Products named: VRAYLAR, AIRSUPRA, QULIPTA, TZIELD, REXULTI, CAPLYTA, MOUNJARO, Ozempic.
Industry payments across MO — which companies pay providers there.
